Lateral Pelvic Lymph Node Dissection in Rectal Cancers. Does it have a Place in Era of Neoadjuvant Chemoradiation?

Nitin Singhal1, Sanket Bankar2 and Avanish Saklani1*

1Department of Surgical Oncology, Tata Memorial Hospital, India
2Department of Colorectal Surgery, Tata Memorial Hospital, India

^*Correspondance to: Avanish P Saklani 

 PDF  Full Text Research Article | Open Access

Abstract:

Globally Cancer of colorectal origin is the 4th most common. Prognosis of colorectal cancers has
improved dramatically in last few decades with the advent of neoadjuvant chemoradiation and
total mesorectal excision. However locoregional recurrence still remains a challenge and there is an
ongoing debate regarding the role of Lateral Pelvic Lymph Node Dissection (LPLND) in rectal cancer
surgery to lessen these recurrences. LPLND is a part of standard surgery for rectal cancers in Japan
with stage T3 or more or with involved mesorectal nodes but has not been adopted by surgeons in
the rest of the world. This difference in treatment approach is due to difference in ideology towards
Lateral Pelvic Nodes (LPN) with Japanese considering LPN as regional disease whereas in the west
LPN is considered as systemic disease. The aim of this article is to review the current evidence on
LPLND and to better define its role especially post-neoadjuvant chemoradiation.

Keywords:

Cite the Article:

Singhal N, Bankar S, Saklani A. Lateral Pelvic Lymph Node Dissection in Rectal Cancers. Does it have a Place in Era of Neoadjuvant Chemoradiation?. World J Surg Surgical Res. 2020; 3: 1204..